A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19

• Main Authors: Vibeke Backer (Author), Ulf Sjöbring (Author), Jesper Sonne (Author), Anne Weiss (Author), Morten Hostrup (Author), Helle Krogh Johansen (Author), Victoria Becker (Author), David P. Sonne (Author), Torben Balchen (Author), Mads Jellingsø (Author), Morten Otto Alexander Sommer (Author)
• Format: Book
• Published: Elsevier, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Coronavirus disease 19 (COVID-19) is spreading globally and treatment options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a broad-spectrum antiviral treatment candidate, optimized for inhalation and intranasal administration (UNI91104) was developed....